Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Charles River Laboratories International, Inc. Common Stock
(NY:
CRL
)
178.52
+3.57 (+2.04%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Charles River Laboratories International, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Discover which S&P500 stocks are making waves on Thursday.
October 16, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.
Via
Chartmill
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption
October 15, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call
October 14, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
3 Reasons to Avoid CRL and 1 Stock to Buy Instead
October 14, 2025
The past six months have been a windfall for Charles River Laboratories’s shareholders. The company’s stock price has jumped 60.1%, hitting $170.64 per share. This was partly due to its solid quarterly...
Via
StockStory
Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks
October 08, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Charles River Laboratories (NYSE:CRL) and its peers.
Via
StockStory
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing
October 08, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
Why Charles River Stock May Struggle In Its Final Phase
October 07, 2025
Adhishthana.com notes Charles River Stock is nearing its Phase 18, with momentum weakening and long-term outperformance looking unlikely.
Via
Benzinga
Charles River Laboratories (CRL) Stock Is Up, What You Need To Know
October 03, 2025
Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 2.6% in the afternoon session after the stock's positive momentum continued, as Barclays upgraded the company to Overweight...
Via
StockStory
What's going on in today's session: S&P500 movers
October 02, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.
Via
Chartmill
Why Charles River Laboratories (CRL) Stock Is Up Today
October 02, 2025
Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 1.9% in the morning session after Barclays upgraded the company to Overweight from Equal-Weight and raised its price target.
Via
StockStory
Topics
Government
Wondering what's happening in today's S&P500 pre-market session?
October 02, 2025
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Via
Chartmill
7 Analysts Assess Charles River: What You Need To Know
October 02, 2025
Via
Benzinga
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years
October 01, 2025
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs.
Via
Benzinga
Topics
Government
Wednesday's session: top gainers and losers in the S&P500 index
October 01, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via
Chartmill
Which S&P500 stocks are moving on Wednesday?
October 01, 2025
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via
Chartmill
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Masimo, Integra LifeSciences, CONMED, IQVIA, and Charles River Laboratories Shares Are Soaring, What You Need To Know
September 30, 2025
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is...
Via
StockStory
Topics
Government
World Trade
What's going on in today's session: S&P500 movers
September 30, 2025
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
Mr Wonderful Kevin O'Leary Says Bitcoin, Ethereum Enough To 'Capture The Promise' Of Crypto, Advises Against 'Irrelevant' Tokens
September 18, 2025
Renowned investor Kevin O’Leary expressed his belief on Wednesday that owning only Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) can capture the majority of the cryptocurrency market’s volat
Via
Benzinga
Charles River Laboratories Announces Chief Financial Officer Transition
September 16, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
September 12, 2025
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive...
Via
Chartmill
Exploring the top movers within the S&P500 index during today's session.
September 12, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer
September 11, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
3 Unpopular Stocks That Concern Us
September 11, 2025
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...
Via
StockStory
Breaking Down Charles River: 6 Analysts Share Their Views
September 09, 2025
Via
Benzinga
This Thomson Reuters Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
September 09, 2025
Via
Benzinga
2 Cash-Producing Stocks Worth Your Attention and 1 We Brush Off
September 09, 2025
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...
Via
StockStory
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
September 08, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
1 S&P 500 Stock with Exciting Potential and 2 We Brush Off
September 05, 2025
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...
Via
StockStory
Topics
Stocks
Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences
September 03, 2025
From
Charles River Laboratories International, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.